Leveraging 3D In Vitro Models for Oncology Drug Discovery

The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.

In this lunch seminar, our expert Maruisz Madej will discuss the need to improve translatability using patient relevant 3D systems such as primary cell cultures and organoids that more faithfully recapitulate tissue architecture and drug responses seen in the clinic.

Don't miss the opportunity to hear Maruisz detail Crown Bioscience's OrganoidXplore™ - the first large panel based organoid screening service for high-throughput screening (HTS) and its role in shortening the path to clinically relevant outcomes.

Register Now

Register Now

Registration for the event is required. Attendance is free and food and drinks will be served, but spaces are limited. We encourage you to register early.

Representatives

Mariusz Madej, PhD Associate Director, Head of Organoid Operations EU and USA, Crown Bioscience